Review summary
Teaching objective: Primary care and gynecologic oncology for a 31-year-old Spanish-speaking woman who has never had cervical screening and presents with abnormal bleeding and anemia: a speculum examination, direct biopsy of a visible cervical lesion with HPV testing and cytology, truthful and culturally sensitive disclosure of the diagnosis to the patient herself first, in her own language, with her choosing who else is told (the teaching contrast with the concealment of her historical diagnosis), FIGO 2018 staging with pelvic MRI and PET-CT, definitive chemoradiation with weekly cisplatin and image-guided brachytherapy for stage IIB disease, fertility and ovarian function counseling before treatment, management of anemia, treatment side effects and radiation-induced menopause, psychosocial support, and survivorship care, on the NCCN cervical cancer guideline, the FIGO 2018 staging system, the ASCCP 2019 management guidelines, the ASCO guidelines on patient-clinician communication, fertility preservation, and anxiety and depression, and the CMID anemia monograph.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| May 7, 1919 | Born in Los Toldos, Province of Buenos Aires. | CLM-0001 |
| October 22, 1945 | Married Juan Perón. | CLM-0002 |
| January 1950 | Fainted; appendectomy. Weakness and anemia from vaginal bleeding followed. | CLM-0003 |
| August 1951 | Advanced cervical cancer found; treated with radium. | CLM-0004 |
| November 1951 | Hysterectomy for cancer that had spread to adjacent pelvic organs; she was not told the diagnosis. | CLM-0005 |
| February 1952 | Recurrence confirmed without telling her; more radiotherapy, later chemotherapy. | CLM-0006 |
| 1952 | Reported prefrontal lobotomy in the last months of her illness (contested reconstruction). | CLM-0008 |
| July 26, 1952 | Died, at 33. | CLM-0007 |
| June 3, 2000 | Barron Lerner's account of her illness published in The Lancet. | CLM-0009 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | She was born Eva María Ibarguren on May 7, 1919, in Los Toldos, a village in the Province of Buenos Aires, Argentina; her marriage contract later gave her birth date as May 7, 1922. | confirmed | Goodwin PB Jr. Perón, Eva (1919-1952). Women in World History: A Biographical Encyclopedia supports |
| D | She married Juan Perón on October 22, 1945, and became Argentina's first lady after his election in 1946. Her work for the poor made her a powerful political figure, and she is best known as Evita. Identity only; her public work anchors the modern social history. |
confirmed | Goodwin PB Jr. Perón, Eva (1919-1952). Women in World History: A Biographical Encyclopedia supports Altman LK. Eva Peron and her doctors' deceit supports Nijensohn DE. Prefrontal lobotomy on Evita was done for behavior/personality modification, not just for pain control. Neurosurg Focus. 2015;39(1):E12 (PMID 26126398) supports |
| D | Her medical ordeal began in January 1950, when she was 30: she fainted and underwent an appendectomy. Despite persistent weakness and anemia from vaginal bleeding, she delayed further tests. The anchor for the modern presenting problem (abnormal bleeding with anemia). Reported from the medical historian Barron Lerner's research; no medical record was fetched. |
probable | Altman LK. Eva Peron and her doctors' deceit supports Goodwin PB Jr. Perón, Eva (1919-1952). Women in World History: A Biographical Encyclopedia context |
| D | In August 1951, much weaker, she developed increasingly severe abdominal pain and fainted again. Examination showed advanced cancer of the cervix, and Argentine doctors treated her with radium, then a standard therapy. After the index date; recorded as history only. The modern diagnosis and treatment are synthetic. |
probable | Altman LK. Eva Peron and her doctors' deceit supports Goodwin PB Jr. Perón, Eva (1919-1952). Women in World History: A Biographical Encyclopedia supports |
| D | In October 1951 the New York cancer surgeon George Pack examined her under anesthesia to confirm the cancer, and in November 1951 he performed extensive surgery, a hysterectomy, because the cancer had spread to adjacent pelvic organs. He entered the operating room after she was anesthetized and left before she awoke. She underwent both procedures believing she had vague female problems, and was not told she had cancer; the secrecy kept the diagnosis from her and from the public during a presidential campaign. After the index date; recorded as history only. The concealment is the teaching contrast for the modern episode, in which the diagnosis is told to her first and fully. |
probable | Altman LK. Eva Peron and her doctors' deceit supports |
| D | When abdominal pain returned in February 1952, her doctors confirmed, again without telling her, that the cancer had recurred. It shrank for a time with more radiotherapy, but the pain returned in May 1952, and chemotherapy failed. After the index date; recorded as history only. |
probable | Altman LK. Eva Peron and her doctors' deceit supports |
| D | She died on July 26, 1952, at 33, never knowing that she had cervical cancer. History only, stated without detail. |
confirmed | Altman LK. Eva Peron and her doctors' deceit supports Goodwin PB Jr. Perón, Eva (1919-1952). Women in World History: A Biographical Encyclopedia supports |
| R | A study by Nijensohn and colleagues, published online in 2011, reported evidence that she underwent a prefrontal lobotomy in Buenos Aires in the last months of her illness, for pain, anxiety and agitation from metastatic cancer; the evidence includes a neurosurgeon's memoirs and press interviews, accounts of people close to her, and skull radiographs. A later paper by the same author argued that the operation was also meant to change her behavior. History only, without detail; a retrospective reconstruction from indirect evidence, not a medical record. Not carried into the modern episode. |
possible | Nijensohn DE, Savastano LE, Kaplan AD, Laws ER Jr. New evidence of prefrontal lobotomy in the last months of the illness of Eva Perón. World Neurosurg. 2012;77(3-4):583-90 (PMID 22079825) supports Nijensohn DE. Prefrontal lobotomy on Evita was done for behavior/personality modification, not just for pain control. Neurosurg Focus. 2015;39(1):E12 (PMID 26126398) context |
| R | The medical historian Barron Lerner, who reported the case in The Lancet in 2000, said it showed how far medical practice and ethics have changed: patients with cancer were then rarely told what they had, whereas most patients in the United States are now told their diagnosis. An interpretation of the concealment; the reason the modern episode documents truthful, culturally sensitive disclosure to the patient herself. |
probable | Altman LK. Eva Peron and her doctors' deceit supports Lerner BH. The illness and death of Eva Perón: cancer, politics, and secrecy. Lancet. 2000;355(9219):1988-91 (PMID 10859055) context |
| D | The Pap smear, which can find cervical cancer at its earliest stage, was developed in 1942, but in 1950 it was not yet standard medical care in the United States or Argentina. Context for the modern screening history, which is synthetic (never screened). |
probable | Altman LK. Eva Peron and her doctors' deceit supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Bleeding after intercourse and between periods, with heavier periods, for about four months, with tiredness and a dull pelvic ache. Never had cervical screening. Speculum examination shows a friable, exophytic mass about 4 cm across on the cervix that bleeds on contact. Punch biopsy, HPV test and cytology taken; urgent gynecologic oncology consultation booked | resolved | confirmed | active | CLM-0003 |
| S | Iron deficiency anemia from chronic blood loss: hemoglobin 9.4 g/dL, mean cell volume 72 fL, ferritin 6 ng/mL, with tiredness and breathlessness on stairs | resolved | confirmed | active | CLM-0003 |
| S | Invasive squamous cell carcinoma of the cervix, HPV 16 positive: an exophytic tumor about 4.5 cm across with clinical involvement of the left parametrium, not reaching the pelvic wall; pelvic MRI and PET-CT ordered for FIGO 2018 staging. Synthetic modern episode linked to her documented cervical cancer | active | confirmed | active | CLM-0003, CLM-0004, CLM-0005 |
| S | Acute cystitis during pelvic chemoradiation: two days of new burning, urgency and cloudy urine on top of mild radiation frequency, without fever or flank pain; urine dipstick positive for leukocyte esterase and nitrite; culture grew Escherichia coli sensitive to nitrofurantoin; neutrophil count and kidney function normal; resolved | resolved | confirmed | active | |
| S | Ovarian failure after pelvic radiation, with hot flashes, night sweats, poor sleep and vaginal dryness two weeks after treatment; FSH 72 mIU/mL and estradiol 14 pg/mL | active | confirmed | active | CLM-0003, CLM-0004, CLM-0005 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-02-09 | Hemoglobin [Mass/volume] in Blood | 9.4 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-02-09 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 72 fL (low) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 2026-02-09 | Leukocytes [#/volume] in Blood by Automated count | 7.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-02-09 | Platelets [#/volume] in Blood by Automated count | 398 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-02-09 | Ferritin [Mass/volume] in Serum or Plasma | 6 ng/mL (low) Reference A ferritin of 30 ng/mL or less indicates iron deficiency |
http://loinc.org · 2276-4 |
| S | 2026-02-09 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | http://loinc.org · 72514-3 |
| S | 2026-02-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-02-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.5-1.1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 117 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | http://loinc.org · 72514-3 |
| S | 2026-02-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | http://loinc.org · 44261-6 |
| S | 2026-02-17 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | http://loinc.org · 70274-6 |
| S | 2026-03-02 | Hemoglobin [Mass/volume] in Blood | 10.2 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-02 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 77 fL (low) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 2026-03-02 | Leukocytes [#/volume] in Blood by Automated count | 6.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-02 | Platelets [#/volume] in Blood by Automated count | 352 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-02 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | http://loinc.org · 72514-3 |
| S | 2026-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | http://loinc.org · 44261-6 |
| S | 2026-03-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | http://loinc.org · 70274-6 |
| S | 2026-05-18 | Hemoglobin [Mass/volume] in Blood | 11.2 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.5-1.1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-18 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | http://loinc.org · 72514-3 |
| S | 2026-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 2026-05-18 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | http://loinc.org · 70274-6 |
| S | 2026-08-17 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-08-17 | Ferritin [Mass/volume] in Serum or Plasma | 48 ng/mL Reference A ferritin of 30 ng/mL or less indicates iron deficiency |
http://loinc.org · 2276-4 |
| S | 2026-08-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 0 | http://loinc.org · 72514-3 |
| S | 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-08-17 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | http://loinc.org · 70274-6 |
| S | 2026-03-27 | Leukocytes [#/volume] in Blood by Automated count | 4.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-27 | Neutrophils [#/volume] in Blood by Automated count | 2.6 10*3/uL Reference 1.5-7.5 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-03-27 | Hemoglobin [Mass/volume] in Blood | 10.4 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-27 | Platelets [#/volume] in Blood by Automated count | 168 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.5-1.1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-09-21 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-05-18 | Follitropin [Units/volume] in Serum or Plasma | 72 m[IU]/mL (high) Reference Typical premenopausal follicular-phase range |
http://loinc.org · 15067-2 |
| S | 2026-05-18 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 14 pg/mL (low) Reference Typical premenopausal range |
http://loinc.org · 2243-4 |
| S | 2026-05-18 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 mg/dL Reference 1.7-2.4 mg/dL |
http://loinc.org · 19123-9 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-02-09 | Body height | 165 cm | 8302-2 | S |
| 2026-02-09 | Body weight | 53 kg | 29463-7 | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 19.5 kg/m2 | 39156-5 | S |
| 2026-02-09 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 2026-02-09 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-02-09 | Heart rate | 92 /min | 8867-4 | S |
| 2026-02-09 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-02-09 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-02-17 | Body height | 165 cm | 8302-2 | S |
| 2026-02-17 | Body weight | 52.8 kg | 29463-7 | S |
| 2026-02-17 | Body mass index (BMI) [Ratio] | 19.4 kg/m2 | 39156-5 | S |
| 2026-02-17 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 2026-02-17 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-02-17 | Heart rate | 90 /min | 8867-4 | S |
| 2026-02-17 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-02-17 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-03-02 | Body height | 165 cm | 8302-2 | S |
| 2026-03-02 | Body weight | 52.5 kg | 29463-7 | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 19.3 kg/m2 | 39156-5 | S |
| 2026-03-02 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 2026-03-02 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-03-02 | Heart rate | 84 /min | 8867-4 | S |
| 2026-03-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-03-02 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-05-18 | Body height | 165 cm | 8302-2 | S |
| 2026-05-18 | Body weight | 50.6 kg | 29463-7 | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 18.6 kg/m2 | 39156-5 | S |
| 2026-05-18 | Systolic blood pressure | 104 mm[Hg] | 8480-6 | S |
| 2026-05-18 | Diastolic blood pressure | 66 mm[Hg] | 8462-4 | S |
| 2026-05-18 | Heart rate | 80 /min | 8867-4 | S |
| 2026-05-18 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-18 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-08-17 | Body height | 165 cm | 8302-2 | S |
| 2026-08-17 | Body weight | 52.4 kg | 29463-7 | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 19.2 kg/m2 | 39156-5 | S |
| 2026-08-17 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 2026-08-17 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-08-17 | Heart rate | 74 /min | 8867-4 | S |
| 2026-08-17 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-17 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-03-27 | Body height | 165 cm | 8302-2 | S |
| 2026-03-27 | Body weight | 51.4 kg | 29463-7 | S |
| 2026-03-27 | Body mass index (BMI) [Ratio] | 18.9 kg/m2 | 39156-5 | S |
| 2026-03-27 | Systolic blood pressure | 106 mm[Hg] | 8480-6 | S |
| 2026-03-27 | Diastolic blood pressure | 66 mm[Hg] | 8462-4 | S |
| 2026-03-27 | Heart rate | 88 /min | 8867-4 | S |
| 2026-03-27 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-27 | Body temperature | 37.2 Cel | 8310-5 | S |
| 2026-03-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-09-21 | Body height | 165 cm | 8302-2 | S |
| 2026-09-21 | Body weight | 52.8 kg | 29463-7 | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 19.4 kg/m2 | 39156-5 | S |
| 2026-09-21 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 2026-09-21 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-09-21 | Heart rate | 72 /min | 8867-4 | S |
| 2026-09-21 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Directs a large charitable foundation that serves low-income families; long working days, frequent public speaking, and travel. Wants to keep working as much as she can
- S Married; no children. She asks that all news about her health be given to her first, and she alone decides what her family and her colleagues are told
- S Language: Spanish is her preferred language for health care; she reads English but wants medical discussions in Spanish. Dr. Barragán speaks Spanish; a professional medical interpreter is booked for clinicians who do not. She declines family members as interpreters
- S Screening: never had cervical screening; did not receive the HPV vaccine
- S Tobacco: never smoked. Alcohol: a glass of wine on social occasions; no drugs
- S Sexual and reproductive health: one male partner, her spouse; no pregnancies; no contraception at present
- S Supports: a close friend and a long-time colleague at the foundation; her work gives her purpose. She would like the hospital's spiritual care team offered when she is in treatment
Functional status
- S Independent; still working full days but exhausted by the evening; breathless climbing two flights of stairs
Mental status
- S Alert, articulate and composed; worried about the bleeding and asks direct questions; PHQ-2 1; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy
- S Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day
- S Nitrofurantoin (monohydrate and macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days
- S Cisplatin 40 mg/m2 (64 mg) intravenous infusion once weekly for five weeks during pelvic radiation, with hydration and antiemetic premedication in the infusion center
- S Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours when needed for nausea in the days after cisplatin
- S Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than 8 a day
- S Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly
- S Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol
Procedures and immunizations
Procedures
- S Punch biopsy of a visible cervical mass at the first visit, with an HPV test and cytology
- S Advance care planning conversation, about 18 minutes, in Spanish
- S Colposcopy of the cervix and vagina, with pelvic and rectovaginal examination, at the gynecologic oncology consultation
- S Pelvic MRI with contrast for staging
- S FDG PET-CT from the skull base to mid-thigh for staging
- S Pelvic external beam radiation therapy, 45 Gy in 25 fractions by intensity-modulated radiation therapy, with weekly cisplatin
- S Image-guided high-dose-rate intracavitary brachytherapy, 28 Gy in 4 weekly fractions
- S FDG PET-CT three months after treatment to assess response
Immunizations
- S 2026-09-21: Influenza vaccine, 2026-2027 season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D January 1950: Fainting followed by an appendectomy (CLM-0003)
- D 1950: Persistent weakness and anemia from vaginal bleeding after the appendectomy, with further tests delayed (CLM-0003)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Diagnosis and stage explained to her directly, in Spanish, with time for questions, before any treatment decision | 2026-03-02 | completed | Diagnosis given to her in person at the second visit and the stage at the third; she made the treatment and fertility decisions herself |
| Hemoglobin 10 g/dL or more before radiation begins | 2026-03-02 | completed | Hemoglobin 10.2 g/dL |
| Chemoradiation and brachytherapy completed within eight weeks | 2026-05-18 | completed | Completed in eight weeks, with five cisplatin doses |
| No evidence of disease on PET-CT and examination three months after treatment | 2026-08-17 | completed | Complete metabolic response; examination without tumor |
| PHQ-9 below 5 by six months | 2026-08-17 | completed | PHQ-9 4 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Diagnosis of a visible cervical lesion: punch biopsy at this visit, an HPV test and cytology, a pregnancy test, a blood count and ferritin; a lesion that looks like cancer is biopsied directly rather than managed by the screening algorithm | completed | GL-ASCCP-2019, GL-NCCN-CERV-2027 |
| Urgent gynecologic oncology consultation, on the day the biopsy result is given: diagnosis, staging, treatment by stage, and fertility and ovarian function counseling | completed | GL-NCCN-CERV-2027, GL-ASCO-FP-2018 |
| Truthful disclosure as she asked: the biopsy result given to her in person, in Spanish, at a visit with time set aside, before anyone else is told; she chooses who is present and who is told; a professional medical interpreter for clinicians who do not speak Spanish, never a family member; information shared step by step, checking what she wants to know | completed | GL-ASCO-COMM-2017 |
| Iron deficiency anemia: ferrous sulfate daily, a blood count at about one month, a ferritin at the end of the course, and acetaminophen rather than anti-inflammatory painkillers for pelvic pain | completed | GL-CMID-2026 |
| FIGO 2018 staging: pelvic MRI and FDG PET-CT, kidney function before cisplatin, an HIV test, and an examination of the vagina and parametria | completed | GL-FIGO-2018, GL-NCCN-CERV-2027 |
| Fertility and ovarian function counseling before treatment: chemoradiation ends the ability to carry a pregnancy and usually ends ovarian function; egg or embryo freezing (about two weeks), surgical moving of the ovaries out of the radiation field, and a gestational carrier were explained; her decision is recorded | completed | GL-ASCO-FP-2018, GL-NCCN-CERV-2027 |
| Psychosocial support: the oncology social worker, the PHQ-9 and GAD-7 at diagnosis, before treatment, at the end of treatment and in follow-up, spiritual care when she asks, and help planning work around treatment | completed | GL-ASCO-ANXDEP-2023, GL-ASCO-COMM-2017 |
| Definitive chemoradiation for stage IIB disease: pelvic external beam radiation 45 Gy in 25 fractions with weekly cisplatin 40 mg/m2, then image-guided high-dose-rate brachytherapy, all within eight weeks; weekly blood count, creatinine and magnesium; ondansetron for nausea and loperamide for diarrhea | completed | GL-NCCN-CERV-2027, GL-FIGO-2018 |
| Survivorship care: a vaginal dilator three times a week, estradiol with progesterone for radiation-induced menopause until the usual age of menopause, gynecologic oncology review every three months for two years, PET-CT about three months after treatment, and warning symptoms to report | completed | GL-NCCN-CERV-2027 |
Planned encounters
- 2026-02-09 — New patient with four months of bleeding after intercourse and between periods and tiredness: history in Spanish, speculum examination, a visible cervical mass biopsied, HPV test and cytology, anemia tests, and her wishes about how results are given (ENC-001)
- 2026-02-17 — Biopsy result given to her in person, and gynecologic oncology consultation the same day: diagnosis, staging plan, treatment options, and fertility and ovarian function counseling (ENC-002)
- 2026-03-02 — Staging results (pelvic MRI and PET-CT), FIGO stage, and her treatment and fertility decisions before chemoradiation (ENC-003)
- 2026-03-27 — Same-day sick visit for burning on passing urine during chemoradiation (ENC-006, unscheduled)
- 2026-05-18 — Review two weeks after completing chemoradiation and brachytherapy: side effects, menopause symptoms, and survivorship care (ENC-004)
- 2026-08-17 — Review three months after treatment: PET-CT response, examination, anemia, mood, and the follow-up plan (ENC-005)
- 2026-09-21 — Periodic adult preventive visit after cancer treatment (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Gynecologic Oncology referral
- Gynecologic Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Gynecologic Oncology referral (XML)
- Gynecologic Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Altman LK. Eva Peron and her doctors' deceit | Tampa Bay Times (St. Petersburg Times) | other |
| SRC-0002 | Goodwin PB Jr. Perón, Eva (1919-1952). Women in World History: A Biographical Encyclopedia | Gale, via Encyclopedia.com | biography |
| SRC-0003 | Lerner BH. The illness and death of Eva Perón: cancer, politics, and secrecy. Lancet. 2000;355(9219):1988-91 (PMID 10859055) | The Lancet | scholarly |
| SRC-0004 | Nijensohn DE, Savastano LE, Kaplan AD, Laws ER Jr. New evidence of prefrontal lobotomy in the last months of the illness of Eva Perón. World Neurosurg. 2012;77(3-4):583-90 (PMID 22079825) | World Neurosurgery | scholarly |
| SRC-0005 | Nijensohn DE. Prefrontal lobotomy on Evita was done for behavior/personality modification, not just for pain control. Neurosurg Focus. 2015;39(1):E12 (PMID 26126398) | Neurosurgical Focus | scholarly |
| SRC-0006 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check direct biopsy of a visible lesion, FIGO 2018 stage IIB by MRI and PET-CT, chemoradiation with weekly cisplatin and brachytherapy within eight weeks, the fertility counseling and her decision, estradiol with progesterone for radiation-induced menopause with the uterus in place, and the documentation of disclosure. |
| provenance review | not_started | Lawrence K. Altman's newspaper report of Barron Lerner's Lancet article (Tampa Bay Times, 2000), the Gale Women in World History entry, and two PubMed abstracts by Nijensohn logged; Lerner's Lancet article itself is cited without its text. The illness claims are D with certainty probable because they rest on Lerner's research as reported; the lobotomy is R, possible. |
| safe messaging review | not_started | The reported lobotomy is recorded once, as history only, marked sensitive, without detail, and is not carried into the modern episode. Political material is limited to what identifies her and explains the secrecy. No modern role is given to any real person. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.